Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC prevails over Medlab

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission's motion for summary judgment is granted in its action against the makers of weight-loss pills alleging false and unsubstantiated advertising claims. The April 21 order issued by the U.S. District Court for the Northern District of California says corporate defendants Medlab, Pinnacle Holdings, Metabolic Research Associates and their principal Scott Holmes are liable for $2.7 million, representing gross sales of a weight-loss product sold as Zyladex, Questral AC and Rapid Loss. The newspaper ads in question claimed a user could "lose up to 15 pounds a week with the amazing formula that forces your body to release fat" and said "not even total starvation can slim you down and firm you up" as quickly as Zyladex Plus can, the ruling said. The court found that small-type disclaimers stating results may vary do not counter misleading weight-loss claims. FTC filed the suit in February 2008 to bar the defendants from further violations (1"The Tan Sheet" Feb. 18, 2008, In Brief)

You may also be interested in...

FTC targets weight loss marketer

The Federal Trade Commission charges a California business with falsely claiming its weight-loss pills cause users to lose weight without dieting or exercise, the agency says Feb. 8. The complaint, filed in the U.S. District Court for the Northern District of California, charges defendants Medlab, Pinnacle Holdings and Metabolic Research Associates and their principal, L. Scott Holmes, with making false and unsubstantiated claims in newspaper supplements for products Zyladex Plus, Questral AC, Questral AC Fat Killer Plus, Rapid Loss 245 and Rapid Loss Rx. The claims included "lose up to 15 pounds a week" and "not even starvation can slim you down and firm you up this fast." FTC says it seeks to "permanently bar the defendants from further violations" as well refunds for affected consumers...

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts